Literature DB >> 15912189

Cribriform-Morular Variant of Papillary Carcinoma: Association with Familial Adenomatous Polyposis - Report of Three Cases and Review of Literature.

Shylashree Chikkamuniyappa1, Jaishree Jagirdar.   

Abstract

We describe a rare variant of papillary thyroid carcinoma (PTC), the Cribriform-Morular Variant (C-MV). A handful of cases have been described in the literature of this entity. They exhibit the morphologic features of a distinctive papillary neoplasm along with solid, cribriform, and squamoid-morular areas. The cribriform and morular features make this a separate entity which could be mistaken for a high grade aggressive thyroid neoplasm. These lesions are usually associated with familial adenomatosis polyposis (FAP) but rarely may be sporadic. We report three cases that we have encountered.

Entities:  

Year:  2004        PMID: 15912189      PMCID: PMC1074509          DOI: 10.7150/ijms.1.43

Source DB:  PubMed          Journal:  Int J Med Sci        ISSN: 1449-1907            Impact factor:   3.738


1. Report of cases

Case 1

Patient was a 32 year old G1P0 white female who presented with an enlarging painless lump in her neck for the preceding two years. Ultrasound revealed a large, lobulated, right lobe mass. Serum level showed: TSH-0.4 μ IU/ml, T3-1.88ng/ml (N: 0.6-1.81 ng/ml), free T4-1.2 ng/dl (N: 0.8-1.8 ng/dl) and 24 hour radio active iodine uptake-37%. She underwent a total thyroidectomy and is currently on adjuvant radioactive iodine. She also underwent a proctocolectomy for multiple colonic polyps and colonic carcinoma.

Case 2

Patient was a 14 year old Latin American female with a gradually enlarging right neck mass for 2 years. CT scan showed several bilateral lesions. Fine needle aspiration showed normal follicular cytology. Serum level showed: TSH-1.31 μ IU/ml, T4-0.92ng/ml (N: 0.6-1.81 ng/ml), free T4-2.6 ng/dl (N: 0.8-1.8 ng/dl) and 24 hour radio active iodine uptake-28%. She underwent a total thyroidectomy with subsequent radioactive ablation. There is no family history of colonic polyposis.

Case 3

Patient was a 34 year old asymptomatic HIV positive female with bilateral neck masses. Fine needle aspiration of the left lobe lesion showed papillary carcinoma. Serum level showed: TSH-1.92 μ IU/ml, free T4-1.1 ng/dl (N: 0.8-1.8 ng/dl) and 24 hour radio active iodine uptake-31%. She underwent a total thyroidectomy with subsequent radioactive ablation. She had a colectomy for multiple colonic polyps.

Gross Pathology

Specimens revealed well-circumscribed, somewhat lobulated tan masses ranging from 1.5-2 cm with multiple satellite nodules. There was no lobe predilection. There was no necrosis or hemorrhage seen. The remainder of the thyroid was lobulated and beefy. Few lymph nodes were also identified.

Microscopic Pathology

The typical nuclear features of PTC could be seen. They were complex branching papillary structures lined by cuboidal cells. The nuclei were hyperchromatic, optically clear with longitudinal grooves and showed eosinophilic, intranuclear and cytoplasmic inclusions as in classic PTC (Fig 1). Some lesions showed an intricate blending of several histological patterns (Fig 2). Cribriform areas had back-to-back follicles with anastomozing bars and arches of cells in the absence of intervening fibrovascular stroma and accounted for 30-50% of the lesions (Fig 3). The solid areas, which were approximately 20-30%, consisted of whorls of cells that form squamoid morules or nests that typically do not show any keratinization or intercellular bridges (Fig 4). No colloid or psamomma bodies were found in the tumors. Case 3 also showed foci of tall and columnar cell features.
Fig 1
Fig 2
Fig 3
Fig 4

2. Comment

Cribriform-Morular Variant (C-MV) of PTC is a rare morphologic entity. It was first described by Harach et al. 1 in association with FAP as a distinctive tumor. A total of 44 cases have been documented so far (See Table 1). We describe three cases, in two of which the patients have FAP. Case 2 was lost to follow-up.
Table 1
Cases Sex/Age (yr) FAP Presentation Main Features APC Mutation in thyroid Treatment Outcome
Harach et al. 1 F/19 Yes Right neck mass 16 separate nodules ND Total thyroidectomy A&W at 25 yrs
F/34 Yes 2 cm ND
F/34 Yes 1 focus ND
F/23 Yes 3 cm ND
Cameselle-Teijeiro and Chan 2 F/30 No Right neck nodule at 6 months 22 mm Absent Hemithroidectomy (R), Subtotal lobectomy (L), Radioactive iodine A&W at 5 yr
F/16 No Left neck nodule for 1 year 15 mm ND Total thyroidectomy, Radioactive iodine A&W at 14 yr
F/20 No Left thyroid nodule 12 mm (R), 23 mm (L) ND Total thyroidectomy A&W at 4 yr
F/19 No Right neck mass 19mm ND Total thyroidectomy Recent case
Yamashita et al.7 F/21 No Anterior neck mass 40 mm ND Surgical resection A&W at 1-2 yr
F/23 No Anterior neck mass 50 mm, LN met + ND Surgical resection A&W at 1-2 yr
F/20 No Anterior neck mass 56 mm ND Surgical resection A&W at 1-2 yr
F/21 No Anterior neck mass 26 mm ND Surgical resection A&W at 1-2 yr
Mizukami et al.8 F/16 No Left neck nodule 20 mm Subtotal thyroidectomy and radical neck dissection A&W at 5 yr
Hizawa et al.9 F/20 Yes Right neck mass 18 mm Exon 15 at codon 1061 Hemithroidectomy (R), and LN dissection A&W at 2 yr
Perrier et al.10 11/12 cases F/15-61 yrs Yes Bilateral : 5 18 mm (0.2-5 cm) multicentric :8 2 cases with LN met's All ND 5 Total thyroidectomy 5 near total thyroidectony 2 lobectomy 2 PO Iodine 10 T4 suppression FU:&mos-30yr, 2 recurred 1 death
Soravia et al.11 F/38 Yes Bilateral mass Multifocal (3-35 mm) capsular and vascular + Exon 15 at codon 698 Total thyroidectomy Recurred and died
F/24 Yes Bilateral mass 20-35 mm, capsular invasion Exon 15 at codon 698 Total thyroidectomy Recurred
F/51 Yes Bilateral mass 6-23 mm Exon 9 at codon 312 Total thyroidectomy NP
Fenton et al.12 F/20 Yes Diagnosis made retrospectively Diagnosis made retrospectively Exon 15 at codon 1061 Total thyroidectomy A&W at 14mos
Cameselle-Teijeiro et al. 6 F/27 Yes Right neck mass x 14 mos 21 mm with capsular and angioinvasion Exon 15 at codon 1309 somatic mutation Total thyroidectomy A&W at 14mos
Cetta et al.13 F/22 Yes NP Encapsulated Exon 15 at codon 1061 NP NP
F/20 Yes NP 8 mm Exon 15 at codon 1309 NP NP
F/36 Yes NP 11 mm Exon 15 at codon 1309 NP NP
Present Cases F/32 Yes Anterior neck Multifocal In process Total thyroidectomy Recent case
Two cases were women in their 30's and the third was a 14 year old. The lesions ranged from 1.5 to 2 cm and were associated with several satellite nodules. There was no lymph node metastasis, capsular or vascular invasion. Our cases are similar to that described by Cameselle-Teijeiro et al. 2 who first proposed the term and did a study on nine cases. All the cases were seen in women between ages of 16-30 years (mean: 21.3). The lesions were predominantly solitary and ranged from 1.5-5.6 cm. All except one showed vascular invasion. Two cases also showed lymph node metastasis. In that study, immunohistochemical stains were positive for thyroglobulin, epithelial membrane antigen, cytokeratin, vimentin, estrogen and progesterone receptors, bcl-2 and Rb proteins. Calcitonin and carcinoembryonic antigen were negative. Follow-up showed seven cases with no recurrences. C-MV of PTC is commonly seen in young females usually less than 30 years of age. The lesions are encapsulated or well-circumscribed. While sporadic forms usually appear as an isolated tumors, the cases associated with FAP are often multifocal due to different somatic mutations added to the germline mutations 3. They display the characteristic histologic pattern of cribriforming akin that seen in breast cancer with morules. Morules appear squamous with no keratinization or cellular bridges. There are also follicles showing papillary, trabecular and solid patterns. There have been several cases showing germline mutations in the APC gene which have also been found in the colonic polyps. Hot spots on codons 1061, 1039 and 698 of the APC gene on exon 15 are frequently identified. It has been proposed that β-catenin immunohistochemistry is a feasible screening method to identify occult FAP in young patients with thyroid tumors 4. Recently Xu B 5 suggested that accumulation of mutant β-catenin contributes to the development of C-MV of PTC. A handful of sporadic cases have also been documented 6. Table 1 summarizes all the cases in the literature. Molecular studies were performed in all our cases and they did not show the hot spots of the APC gene. C-MV carries a better prognosis than the other aggressive variants of PTC (tall cell, columnar, diffuse sclerosing and diffuse follicular) and poorly differentiated carcinoma. Tall cell variant lacks morular, cribriform and spindle cell areas. Columnar cell variant presents in older males. The encapsulated form of columnar cell variant is common in females and histologically shows greater overlap with C-MV but does not have the morules and cribriform pattern. Hyalinizing trabecular tumor shows a zellballen pattern in a hyalinized amyloid-like background. Poorly differentiated (insular) carcinoma shows areas mimicking cribriform structures but lacks morules and is associated with a higher proliferation index and necrosis. This morphologic variant should be borne in mind by pathologists because of its characteristic pattern. The clinician should be alerted to exclude FAP along with appropriate family screening. In 25-30% of cases, this might provide the first indicator of an underlying FAP syndrome.
  13 in total

Review 1.  Cribriform-morular variant of papillary carcinoma: a distinctive variant representing the sporadic counterpart of familial adenomatous polyposis-associated thyroid carcinoma?

Authors:  J Cameselle-Teijeiro; J K Chan
Journal:  Mod Pathol       Date:  1999-04       Impact factor: 7.842

2.  Cribriform-morular variant of papillary thyroid carcinoma: a pathological and molecular genetic study with evidence of frequent somatic mutations in exon 3 of the beta-catenin gene.

Authors:  Bing Xu; Katsuhiko Yoshimoto; Akira Miyauchi; Seiji Kuma; Noriko Mizusawa; Mitsuyoshi Hirokawa; Toshiaki Sano
Journal:  J Pathol       Date:  2003-01       Impact factor: 7.996

3.  Thyroid cancer in patients with familial adenomatous polyposis.

Authors:  N D Perrier; J A van Heerden; J R Goellner; E D Williams; H Gharib; P Marchesa; J M Church; V W Fazio; D R Larson
Journal:  World J Surg       Date:  1998-07       Impact factor: 3.352

4.  Somatic but not germline mutation of the APC gene in a case of cribriform-morular variant of papillary thyroid carcinoma.

Authors:  J Cameselle-Teijeiro; C Ruiz-Ponte; L Loidi; J Suarez-Peñaranda; J Baltar; M Sobrinho-Simoes
Journal:  Am J Clin Pathol       Date:  2001-04       Impact factor: 2.493

5.  Thyroid carcinoma associated with familial adenomatous polyposis.

Authors:  F Cetta; P Toti; M Petracci; G Montalto; A Disanto; F Lorè; A Fusco
Journal:  Histopathology       Date:  1997-09       Impact factor: 5.087

6.  Association between thyroid cancer of cribriform variant and familial adenomatous polyposis.

Authors:  K Hizawa; M Iida; T Yao; K Aoyagi; Y Oohata; R Mibu; K Yamasaki; T Hirata; M Fujishima
Journal:  J Clin Pathol       Date:  1996-07       Impact factor: 3.411

Review 7.  Familial adenomatous polyposis associated thyroid carcinoma: a distinct type of follicular cell neoplasm.

Authors:  H R Harach; G T Williams; E D Williams
Journal:  Histopathology       Date:  1994-12       Impact factor: 5.087

8.  Peculiar nuclear clearing composed of microfilaments in papillary carcinoma of the thyroid.

Authors:  T Yamashita; Y Hosoda; K Kameyama; M Aiba; K Ito; Y Fujimoto
Journal:  Cancer       Date:  1992-12-15       Impact factor: 6.860

9.  Familial adenomatous polyposis-associated thyroid cancer: a clinical, pathological, and molecular genetics study.

Authors:  C Soravia; S L Sugg; T Berk; A Mitri; H Cheng; S Gallinger; Z Cohen; S L Asa; B V Bapat
Journal:  Am J Pathol       Date:  1999-01       Impact factor: 4.307

10.  Nuclear localization of immunoreactive beta-catenin is specific to familial adenomatous polyposis in papillary thyroid carcinoma.

Authors:  K Kurihara; S Shimizu; J Chong; T Hishima; N Funata; H Kashiwagi; H Nagai; M Miyaki; M Fukayama
Journal:  Jpn J Cancer Res       Date:  2000-11
View more
  7 in total

Review 1.  Cribriform morular variant of papillary thyroid carcinoma in a patient with an incidental neck lump: a case report and review of the literature.

Authors:  Ester Chai Kheng Yeoh; Ling Choo Lim; Siok Bian Ng; Kok Yang Tan; C Rajasoorya
Journal:  Endocr Pathol       Date:  2014-09       Impact factor: 3.943

2.  Familial Adenomatous Polyposis-Associated Papillary Thyroid Cancer.

Authors:  Shahrun Niza Abdullah Suhaimi; Nadzrin Nazri; Mat Latar Nani Harlina; Nurismah Md Isa; Rohaizak Muhammad
Journal:  Malays J Med Sci       Date:  2015 Jul-Aug

3.  Cribriform-morular variant of papillary thyroid carcinoma: an indication to screen for occult FAP.

Authors:  Rachel A Levy; Vanessa W Hui; Rupa Sood; Stephanie Fish; Arnold J Markowitz; Richard J Wong; José G Guillem
Journal:  Fam Cancer       Date:  2014-12       Impact factor: 2.375

4.  Papillary thyroid carcinoma: differential diagnosis and prognostic values of its different variants: review of the literature.

Authors:  Rogelio Gonzalez-Gonzalez; Ronell Bologna-Molina; Ramón Gil Carreon-Burciaga; Marcelo Gómezpalacio-Gastelum; Nelly Molina-Frechero; Sirced Salazar-Rodríguez
Journal:  ISRN Oncol       Date:  2011-12-06

5.  Cribriform-Morular Thyroid Carcinoma Is a Distinct Thyroid Malignancy of Uncertain Cytogenesis.

Authors:  Vania Nosé; Ozgur Mete; Baris Boyraz; Peter M Sadow; Sylvia L Asa; Dora Dias-Santagata
Journal:  Endocr Pathol       Date:  2021-05-21       Impact factor: 4.056

Review 6.  An Updated Review of Cribriform Carcinomas with Emphasis on Histopathological Diagnosis and Prognostic Significance.

Authors:  Giovanni Branca; Antonio Ieni; Valeria Barresi; Giovanni Tuccari; Rosario Alberto Caruso
Journal:  Oncol Rev       Date:  2017-03-10

7.  Cribiform-morular variant of papillary thyroid carcinoma and familial adenomatous polyposis: Report of a case.

Authors:  Mario Giuffrida; Federica De Giorgi; Federico Cozzani; Matteo Rossini; Elena Bonati; Paolo Del Rio
Journal:  Acta Biomed       Date:  2021-04-30
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.